E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial

详细信息    查看全文

• 作者：Brigid O’Brien ; Oliver Knight-West ; Natalie Walker…
• 关键词：Electronic cigarette/e ; cigarette ; Tobacco ; Smoking cessation ; Mental illness ; Nicotine ; Harm reduction
• 刊名：Tobacco Induced Diseases
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：13
• 期：1
• 全文大小：386 KB
• 参考文献：1. Brown, S, Inskip, H, Barraclough, B (2000) Causes of the excess mortality of schizophrenia. Br J Psychiatry 177: pp. 212-7 CrossRef
  2. Banham, L, Gilbody, S (2010) Smoking cessation in severe mental illness: what works?. Addiction 105: pp. 1176-89 CrossRef
  3. Campion, J, Checinski, K, Nurse, J, McNeill, A (2008) Smoking by people with mental illness and benefits of smoke-free mental health services. Adv Psychiatr Treat 14: pp. 217-28 CrossRef
  4. Smith, PH, Homish, GG, Giovino, GA, Kozlowski, LT (2014) Cigarette smoking and mental illness: a study of nicotine withdrawal. Am J Public Health 104: pp. e127-33 CrossRef
  5. Smith, PH, Mazure, CM, McKee, SA (2014) Smoking and mental illness in the US population. Tob Control 23: pp. e147-53 CrossRef
  6. Callaghan, RC, Veldhuizen, S, Jeysingh, T, Orlan, C, Graham, C, Kakouris, G (2014) Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 48: pp. 102-10 CrossRef
  Vital signs: Current cigarette smoking among adults aged aged ?18 Years—United States, 2009-011. MMWR Morb Mortal Wkly Rep 62: pp. 81-7
  7. Wittchen, HU, Jacobi, F (2005) Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15: pp. 357-76 CrossRef
  8. McManus S, Meltzer H, Brugha T, Bebbington P, Jenkins R. Adult Psychiatric Morbidity Survey 2007. Results of a household survey. The NHS Health & Social Care Information Centre, Social Care Statistics; 2009. http://www.hscic.gov.uk/catalogue/PUB02931/adul-psyc-morb-res-hou-sur-eng-2007-rep.pdf
  9. McCreadie, R, Kelly, C (2000) Patients with schizophrenia who smoke. Private disaster, public resource. Br J Psychiatry 176: pp. 109 CrossRef
  10. Siru, R, Hulse, GK, Tait, RJ (2009) Assessing motivation to quit smoking in people with mental illness: a review. Addiction 104: pp. 719-33 CrossRef
  11. Tsoi, DT, Porwal, M, Webster, AC (2013) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2: pp. CD007253
  12. Pachas, G, Cather, C, Pratt, S, Hoeppner, B, Nino, J, Carlini, S (2012) Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. J Dual Diagn 8: pp. 1178-125 CrossRef
  13. Rüther, T, Bobes, J, De Hert, M, Svensson, TH, Mann, K, Batra, A (2014) EPA Guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 29: pp. 65-82 CrossRef
  14. van der Meer, RM, Willemsen, MC, Smit, F, Cuijpers, P (2013) Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 8: pp. CD006102
  15. Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014. doi:10.1007/s00406-014-0551-3
  16. Parker, C, McNeill, A, Ratschen, E (2012) Tailored tobacco dependence support for mental health patients: a model for inpatient and community services. Addiction 107: pp. 18-25 CrossRef
  Smoking and Mental Health. RCP, London
  17. Cook, BL, Wayne, GF, Kafali, EN, Liu, Z, Shu, C, Flores, M (2014) Trends in smoking among adults with mental illness and association between mental heal
• 刊物主题：Public Health; Behavioural Sciences; Internal Medicine; Health Psychology;
• 出版者：BioMed Central
• ISSN：1617-9625

文摘

Background People with mental illness have higher rates of smoking than the general population and are at greater risk of smoking-related death and disability. In smokers from the general population, electronic cigarettes (e-cigarettes) have been shown to have a similar effect on quit rates as nicotine replacement therapy, but little is known about their effect in smokers with mental illness. Methods Secondary analysis of data from the ASCEND trial involving 657 dependent adult smokers motivated to quit, randomised to 16?mg nicotine e-cigarette, 21?mg nicotine patch, or 0?mg nicotine e-cigarette, with minimal behavioural support. Using self-reported medication use and the Anatomical Therapeutic Chemical Classification System, we identified 86 participants with mental illness and analysed their cessation and smoking reduction outcomes. Results For e-cigarettes alone, and all interventions pooled, there was no statistically significant difference in biochemically verified quit rates at six months between participants with and without mental illness, nor in smoking reduction, adverse events, treatment compliance, or acceptability. Rates of relapse to smoking were higher in participants with mental illness. Among this group, differences between treatments were not statistically significant for cessation (patch 14% [5/35], 16?mg e-cigarette 5% [2/39], 0?mg e-cigarette 0% [0/12], p--.245), adverse events or relapse rates. However, e-cigarette users had higher levels of smoking reduction, treatment compliance, and acceptability. Conclusions The use of e-cigarettes for quitting appears to be equally effective, safe, and acceptable for people with and without mental illness. For people with mental illness, e-cigarettes may be as effective and safe as patches, yet more acceptable, and associated with greater smoking reduction. Trial registration Australian New Zealand Clinical trials Registry, number: ACTRN12610000866000.